Contribute Try STAT+ Today

Drug developers have tried for decades without success to develop treatments for sepsis, a brutal infection that can lead to organ failure. Now a leading immunotherapy company is taking the novel approach of using cutting-edge cancer drugs to try to beat back the deadly infection of the blood.

Sepsis is implicated in up to half of hospital deaths, amounting to hundreds of thousands of deaths in the US per year. Doctors can use antibiotics to help control septic infections, but they don’t work in many cases. And when the immune system ramps up in its attempt to overcome the bacteria, it often inflicts collateral damage on the heart, kidney, lungs, liver, and brain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.